Drugs / WVE-N531
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04906460 | Sep 2021 → Jun 2026 overdue | Duchenne muscular dystrophy | Wave Life Sciences USA, Inc. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07209332 | Dec 2025 → Mar 2029 expected | Duchenne muscular dystrophy | Wave Life Sciences USA, Inc. | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WVE-N531 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04906460 ↗ |
| Modality | Antisense oligonucleotide | “WVE-N531 is an antisense oligonucleotide (ASO)” NCT04906460 ↗ |
| Route | Intravenous | “intravenous (IV) WVE-N531” NCT04906460 ↗ |